3 d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii
This presentation is the property of its rightful owner.
Sponsored Links
1 / 9

3 D (Paritaprevir -Ritonavir -Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II PowerPoint PPT Presentation


  • 72 Views
  • Uploaded on
  • Presentation posted in: General

Phase 3. Treatment Experienced. 3 D (Paritaprevir -Ritonavir -Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II. Zeuzem S, et al. N Engl J Med. 2014;370:1604-14. 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE -II: Study Design.

Download Presentation

3 D (Paritaprevir -Ritonavir -Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


3 d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii

Phase 3

TreatmentExperienced

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1SAPPHIRE-II

Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.


3d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii study design

3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Study Design

Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.


3d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii regimens

3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Regimens

0

12

24

36

Week

Double blind

3D + Ribavirin

Active N = 297

SVR12

Open label (data pending)

Placebo

3D + Ribavirin

PlaceboN = 97

SVR12

3D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir

Drug Dosing3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg)

Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.


3 d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii

3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II Study: Baseline Characteristics

Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.


3d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii results

3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Results

SAPPHIRE-II: Results by Genotype 1 Subtype

286/297

166/173

119/123

Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.


3d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii results1

3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Results

SAPPHIRE-II: Results by Prior Treatment Response

286/297

82/86

65/65

139/146

Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.


3d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii study key adverse events

3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II Study: Key Adverse Events

Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.


3d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii conclusions

3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1SAPPHIRE-II: Conclusions

Source: Zeuzem S, et al. N Engl J Med. 2014;370:1604-14.


3 d paritaprevir ritonavir ombitasvir dasabuvir rbv in gt1 sapphire ii

This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects.

Hepatitis C Onlinewww.hepatitisc.uw.edu

Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.


  • Login